On-demand Scientific Programme (All times are CET)

Click on the session title that has an icon next to it to view the on-demand recording

To display the video full-screen click on the icon

  SESSION I – Hodgkin’s Disease
Chairs: Andreas Engert (Cologne) and Camille Laurent (Toulouse)
  Diagnostics The boundaries of Hodgkin Lymphoma
Stefano Pileri (Milan)
  First line Treatment Early stages
Marc André (Namur, Yvoir)
  First line Treatment Intermediate/Advanced stages
Andreas Engert (Cologne)
  Relapsed Disease
Pier Luigi Zinzani (Bologna)
  Refractory/relapsed hodgkin lymphoma: the profile of patients referred to autologous stem cell transplantation
Maria Eduarda Couto (Porto)
  Discussion Q & A
  DEBATE I: Is there still a role for combined modality therapy for early stage cHL?
Chair: Marc André (Namur, Yvoir)
Joachim Yahalom (New York)
Peter Johnson (Southampton)
  SATELLITE SYMPOSIUM: New insights in WM & MCL treatment landscape
Chairs: Gilles Salles (New York), Jorge J. Castillo (Boston)
Speakers: Olivier Tournilhac (Clermont-Ferrand), Martin H. Dreyling (Munich), Jorge J. Castillo (Boston)
This educational symposium is organized and funded by Beigene
  SESSION II – T-Cell Lymphoma
Chairs: Catherine Thieblemont (Paris) and Pier Luigi Zinzani (Bologna)
  Peripheral T-cell lymphomas: diagnosis and refinement through understanding
Philippe Gaulard (Créteil)
  First line treatment
Owen O’Connor (New York)
  Salvage treatment
Pier Luigi Zinzani (Bologna)
  How clinical trials and the latest update of the WHO classification are shaping current and future therapies for T-cell lymphoma including the use of stem cell transplant – Towards more subtype-specific approaches?
Francesco d’Amore (Aarhus)
  Discussion Q & A
  ROUNDTABLE I – Future directions in T-Cell Lymphoma
Chair: Camille Laurent (Toulouse)
  Allogeneic stem cell transplantation for PTCL patients: Why and when?
Ghandi Laurent Damaj (Caen)
  Perspectives of integrating immunotherapy in PTCL treatment algorithms
Gerald Wulf (Göttingen)
  Discussion Q & A
  SESSION III – Follicular Lymphoma
Chairs: Christian Buske (Ulm) and Franck Morschhauser (Lille)
Wolfram Klapper (Kiel)

Question: Hi Dr Klapper, does seeing necrosis adjacent to low grade follicular lymphoma make you suspicious for DLBCL? Can you see necrosis in just low grade follicular lymphoma?

Answer: We breifly touthed this issue in the live discussion. Necrosis is a feature that can be accompanied with low grade FL (Grade 1, 2 or 3a). The reason is, that a small subgroup of FL (I am not sure how many) are vasculotropic, invade vessel walls and lead to vascular obstruction. As a conseqience the lymph node frequently becomes completely necrotic. Necrosis is a feature that is not seen in other low grade lymphomas. It may be seen in high grade lymphomas such as DLBCL. However, in the latter it is usually not so extended as in FL. Thus, if there is extended (subtotal) necorsis of a sufficiently large lymph node biopsy (ideally a surgical excision biopsy), you should suspect FL rather than a transformed lymphoma.

Question: Prof. Klapper: How do you consider the presence of a DLBCL component on an FL biopsy? Could we consider this as HT? Prof. Luminari: How do you treat those patients, as FL or DLBCL?

Answer: In cases with an area resembling DLBCL, I consider this a transformation. However, at first diagnosis of a FL, transformation is rare. In fact indirect evidence suggest that pathologists overestimate the rate of transformation at first diagnosis. THe indirect evidence I am referring to are clinical data that show an outcome of FL trasnformed at first diagnosis comparted to untrsformed (normal) FL. In my opinion, many of the FL that are signed out nby pathologist as transformed at the time of first presentation/diagnosis may just “mimic” transformation. As I mentioned in the live discussion the conditions that mimic transformation are (i) diffuse growth (ii) necrosis (iii) presence of MYC translocations or double hit despite low grade morphology and (iv) high ki67 (more than 50%) in otherwise low grade lymphoma. Thus, check clinical presentation ehen you get a pathology report with a combined FL/DLBCL at first diagnosis to see if clinically transformation is comprehensible and discuss with your pathologist, when you feel that there is a discepancy between clinical presentation and path report.

  First line
Stefano Luminari (Modena)
  Salvage treatment
Franck Morschhauser (Lille)

Question: Do you recommend MRD testing by ASO-PCR or NGS after therapy? Bone marrow or peripheral blood?

Answer: Both techniques are still mainly restricted to clinical trials. NGS appears premising but it’s early days and neither one nor the other has clinical implications so far.

Question: What is the role of maintenance therapy in R/R FL? In which cases would you recommend a maintenance therapy in case patients had already a maintenance therapy in 1. Line? And thank you all for the interesting presentations! (Wiebke Rösler, Switzerland)

Answer: In theory, a patient who would have benefited from maintenance in first-line (i.e somebody whose PFS is longer than the median) could be eligible for a second maintenance round in relapse. However, in real life, most patients given maintenance in first-line do not receive maintenance as part of second line.

Question: To prof Franck morschauser: what is your opinion regarding mosunetuzumab in R/R FL?

Answer: Mosun is one of the 1 to 1 bispecifics with good results in FL. Safety profile seems favorable and sub-cutaneous formulation makes it attractive. One concern is that Mosun doesn’t not allow the concomitant use of rituximab one of the most important step forward in FL if we believe in ADCC. The future and other trials with bipsecifics will tell if this only a theoretical concern.

  Challenges in FL – POD24
Emmanuel Bachy (Lyon)
  EZH2 gain-of-function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma: a preliminary analysis on 908 patients
Csaba Bödör (Budapest)
  Discussion Q & A
  SATELLITE SYMPOSIUM: Immunotherapy: the new cornerstone of lymphoma care
Chair: Stefano Luminari (Reggio Emilia)
Speakers: Stefano Luminari (Reggio Emilia), Andrew Davies (Southampton) and Marc André (Namur)
This educational symposium is organized and funded by Celgene | A Bristol Myers Squibb Company
  Mentored Poster Walk
  DEBATE II: Can we avoid chemotherapy in FL?
Chair: Gilles Salles (New York)
Nathan Fowler (Houston)
Umberto Vitolo (Turin)
  SESSION IV – Rare Lymphomas – Marginal Zone Lymphoma and Waldenström Macroglobulinemia
Chairs: Catherine Thieblemont (Paris) and Christian Buske (Ulm)
Maurilio Ponzoni (Milan)
  Waldenström macroglobulinemia
Jorge J. Castillo (Boston)
  Marginal Zone Lymphoma
Emanuele Zucca (Bellinzona)
  Macroglobulinemia Waldenström– a single centre experience
Cátia Sol Reis (Porto)
  Discussion Q & A
  ROUNDTABLE II – Where to go in rare B-Cell Lymphomas
Chair: Markus Raderer (Vienna)
  Marginal Zone Lymphoma – case reports
Alexander Grunenberg (Ulm)
  What we can learn from a single case of ENMZL with Multiple Mucosal Sites presentation?
Izidore S. Lossos (Miami)
  SESSION V – Mantle Cell Lymphoma
Chairs: Olivier Hermine (Paris) and Elias Campo (Barcelona)
Elias Campo (Barcelona)
  First line treatment
Steven Le Gouill (Nantes)
  Salvage treatment
Martin H. Dreyling (Munich)
  BTK failures
Olivier Hermine (Paris)
  TP53 status in Mantle Cell Lymphoma (MCL) – a 10-year single center experience
Ezzat Elhassadi (Waterford)
  Discussion Q & A
  SESSION VI – Diffuse Large B-Cell Lymphoma
Chairs: Catherine Thieblemont (Paris) and Davide Rossi (Bellinzona)
Thierry Molina (Paris)

Question: What does Mr. Molina think, in how many years will the genetic subgroups (e.g. C0-C5) be tested in everyday day routine?

Answer: Today in routine practice more and more genetic tests are implemented in DLBCL such as FISH , targeted gene expression tools or targeted NGS
The new genetic subgroups in DLBCL NOS will be implemented once reproducibility issues between labs proved , feasibility on ffpe demonstrated and utility being demonstrated when evaluated prospectively in clinical protocols for DLBCL
My guess is that within the next three years we will be able to better define subgroups also with the help of AI
Thierry Molina.

  First line
Andy Davies (Southampton)
Jason Westin (Houston)
  CAR – T cells
Stephen Schuster (Philadelphia)

Question: If there’s no interference between pola and CAR-T, then does it mean that bystander activation of non CAR-T cells of the microenvironment is a key mechanism ?

Answer: We believe that there is a significant bystander reaction during CAR-T therapy that involves non-CAR-T cells. This has been observed in biopsies obtained during therapy. Polatuzumab (with rituximab) is a good third line therapy because it does not deplete T cells and allows successful apheresis and T cell collection.

  Improved personalized survival prediction of patients with diffuse large b-cell lymphoma using gene expression profiling
Miguel Cid López (Santiago de Compostela)
  Discussion Q & A
  Key Note Lecture: Biology and New Targets in DLBCL
Riccardo Dalla Favera (New York)
  SATELLITE SYMPOSIUM How I treat relapsed/refractory disease – DLBCL and CLL
Chair: Gilles Salles (New York)
Speakers: Marie-Jose Kersten (Amsterdam), Kieron Dunleavy (Washington), Francesc Bosch (Barcelona), Astrid Pavlosky (Buenos Aires)
This educational symposium is organized and funded by the Lymphoma Hub
  DEBATE III: Do we still need ASCT in MCL?
Chair: Olivier Hermine (Paris)
Marco Ladetto (Alessandria)
Georg Hess (Mainz)
  SESSION VII – Novel Therapeutic Concepts in B-Cell Lymphomas
Chair: Corinne Haioun (Créteil)
  Genetics-driven epigenetic dysregulation in lymphoma: therapeutic implications
Laura Pasqualucci (New York)
  Next generation CAR-T cells
Renier Brentjens (New York)
  Checkpoint Inhibitors and bispecific antibodies
Stephen Ansell (Rochester)
  Bone marrow microenvironment lymphocytes measured by flow cytometry can predict early relapse in diffuse large B cell lymphoma patients
Laura Korin (Buenos Aires)
  Discussion Q & A
  Closing Remarks